Specialized Pro-Resolving Mediators Reduce Scarring After Cleft Lip Repair

Papathanasiou, Evgenia; Scott, Andrew R.; Trotman, Carroll Ann; Beale, Corinna; Price, Lori Lyn; Huggins, Gordon S.; Zhang, Yang; Georgakoudi, Irene; Dyke, Thomas E. Van

doi:10.3389/fimmu.2022.871200

Cited by 2 publications

(4 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Preclinical studies have shown LXA 4 -ME limits scarring after cleft lip repair in rabbits, suggesting new therapeutic opportunities in the prevention and management of pathologic scarring in. 55 The present study hypothesized that certain scar subsites may also be associated with treatment type and response to treatment. Alo et al found that different scar locations correspond with certain morphological patterns, postulating that location and morphology may influence treatment.…”

Section: Discussionmentioning

confidence: 88%

“…Emerging evidence suggests that specialized pro‐resolving mediators of inflammation such as methyl‐ester of pro‐resolving lipid mediator lipoxin A 4 (LXA 4 ‐ME) prevent chronic inflammation, thus accelerating wound healing after cleft lip repair and facilitating healthy tissue remodeling 25 . Preclinical studies have shown LXA 4 ‐ME limits scarring after cleft lip repair in rabbits, suggesting new therapeutic opportunities in the prevention and management of pathologic scarring in 55 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Presentation, Management, and Outcomes of Pathologic Scars Within a Pediatric Otolaryngology Practice

Zaccardelli,

Harb,

Papathanasiou

et al. 2024

The Laryngoscope

Self Cite

View full text Add to dashboard Cite

ObjectivesThis study aims to review the spectrum of scarring that may present to an urban, pediatric otolaryngology practice and determine if associations exist between race, scar location, treatment modality, and outcomes following interventions for scarring.MethodsRetrospective cohort study among 115 pediatric patients with 138 unique keloids or hypertrophic scars (HTS), and 141 children presenting for tonsillectomy at Tufts Medical Center. Age at presentation and sex assigned at birth were collected for both populations. For those presenting for pathologic scars, income quintile, self‐identified race/ethnicity, anatomical location, treatment number and type, and clinical outcome were also analyzed. Multivariate analyses calculated adjusted odds ratios (aORs) and 95% confidence intervals to assess associations between scar subsite, intervention type, and persistence after treatment.ResultsCompared to individuals presenting for tonsillectomy, a disproportionate percentage of patients presenting for scarring identified as Black (26.6% vs. 13.5%) or Asian (17.4% vs. 7.1%, p = 0.016) or were male (61.7% vs. 49.7%, p = 0.053). Individuals identifying as Black or Asian were more likely to present with ear lobe and neck scars, respectively (50.0% vs. 45.5%, p = <0.001). Ear scars were significantly more likely to receive excision at initial treatment (aOR = 5.86 [1.43–23.96]) compared to other subsites, and were more likely to require >1 treatment (aOR = 5.91 [1.53–22.75]).ConclusionAmong pediatric patients presenting with keloids or HTS, children who identified as Black or Asian were more likely to present with ear and neck scars, respectively. Ear scars were frequently treated with excision and appear more likely to require adjuvant treatments and multiple interventions.Level of EvidenceLevel III Laryngoscope, 2024

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Presentation, Management, and Outcomes of Pathologic Scars Within a Pediatric Otolaryngology Practice

Zaccardelli,

Harb,

Papathanasiou

et al. 2024

The Laryngoscope

Self Cite

View full text Add to dashboard Cite

show abstract

“…77 Decreased inflammation resulting from resolvin treatment appears to alter scar formation as well, improving collagen alignment and visual scar assessment in a model of cleft lip palate surgery. 78 Wide range of actions of pro-resolving mediators in promoting tissue regeneration, controlling infections, and facilitating the resolution of inflammation has been recently reviewed. 79 It remains to be seen if VNS can upregulate pro-resolving mediators in skin wounds and contribute to wound repair.…”

Section: How Vns Can Modulate Cutaneous Inflammationmentioning

confidence: 99%

“…A wound dressing that contains abundant SPMs (LIPINOVA®, Solutex, Madrid, Spain) reduced pro‐inflammatory macrophages, while increasing anti‐inflammatory Mφ2 polarisation and promoting wound closure in db/db mice 77 . Decreased inflammation resulting from resolvin treatment appears to alter scar formation as well, improving collagen alignment and visual scar assessment in a model of cleft lip palate surgery 78 . Wide range of actions of pro‐resolving mediators in promoting tissue regeneration, controlling infections, and facilitating the resolution of inflammation has been recently reviewed 79 .…”

Section: Pre‐clinical Studiesmentioning

confidence: 99%

Vagus nerve stimulation: Potential for treating chronic wounds

Budhiraja,

Mehta,

Alhamo

et al. 2024

Wound Repair Regeneration

View full text Add to dashboard Cite

Vagus nerve stimulation (VNS) has been approved as a treatment for various conditions, including drug‐resistant epilepsy, migraines, chronic cluster headaches and treatment‐resistant depression. It is known to have anti‐inflammatory, anti‐nociceptive and anti‐adrenergic effects, and its therapeutic potential for diverse pathologies is being investigated. VNS can be achieved through invasive (iVNS) or non‐invasive (niVNS) means, targeting different branches of the vagus nerve. iVNS devices require surgical implantation and have associated risks, while niVNS devices are generally better tolerated and have a better safety profile. Studies have shown that both iVNS and niVNS can reduce inflammation and pain perception in patients with acute and chronic conditions. VNS devices, such as the VNS Therapy System and MicroTransponder Vivistim, have received Food and Drug Administration approval for specific indications. Other niVNS devices, like NEMOS and gammaCore, have shown effectiveness in managing epilepsy, pain and migraines. VNS has also demonstrated potential in autoimmune disorders, such as rheumatoid arthritis and Crohn's disease, as well as neurological disorders like epilepsy and migraines. In addition, VNS has been explored in cardiovascular disorders, including post‐operative atrial fibrillation and myocardial ischemia–reperfusion injury, and has shown positive outcomes. The mechanisms behind VNS's effects include the cholinergic anti‐inflammatory pathway, modulation of cytokines and activation of specialised pro‐resolving mediators. The modulation of inflammation by VNS presents a promising avenue for investigating its potential to improve the healing of chronic wounds. However, more research is needed to understand the specific mechanisms and optimise the use of VNS in wound healing. Ongoing clinical trials may support the use of this modality as an adjunct to improve healing.

show abstract

Specialized Pro-Resolving Mediators Reduce Scarring After Cleft Lip Repair

Cited by 2 publications

References 69 publications

Presentation, Management, and Outcomes of Pathologic Scars Within a Pediatric Otolaryngology Practice

Presentation, Management, and Outcomes of Pathologic Scars Within a Pediatric Otolaryngology Practice

Vagus nerve stimulation: Potential for treating chronic wounds

Contact Info

Product

Resources

About